A Phase 1/2 interventional study of GSK2256294 and Placebo in Subarachnoid Hemorrhage, Aneurysmal, Delayed Cerebral Ischemia and Vasospasm, Cerebral, sponsored by Oregon Health and Science University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-22.
Sponsored by Oregon Health and Science University · Phase 1/2, Interventional, and Treatment
Among 149 studies in Subarachnoid Hemorrhage with a site in United States — 31 open to participants now, 37 under way, 2 of them phase 3. Subarachnoid Hemorrhage · United States.
Among the 149 studies in Subarachnoid Hemorrhage with a site in United States, this one is the 64th largest by enrollment of the 107 interventional ones that give a count, is one of 9 that started in 2018, is one of 13 in phase 1/2, and was the 89th registered.
510 studies on the registry are indexed under Subarachnoid Hemorrhage; 128 are open to participants now.
Browse Subarachnoid Hemorrhage studies →31 of the 149 studies in Subarachnoid Hemorrhage with a site in United States are open now. Recruiting first, the newest first:
Columbia University · Sites in United States, Brazil, Canada and 2 more countries
Daniel Raper, MBBS · Sites in United States
University of Louisville · Sites in United States
University of Florida · Sites in United States
Marshall Holland · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 89 Subarachnoid Hemorrhage studies recruiting now, 56 (63%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
149 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 33 · Phase 3 11 · Phase 4 17
First in 1999; this study’s year is marked. 9 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 57 across 264 interventional studies indexed under Subarachnoid Hemorrhage.
Median enrollment 30 across the 107 interventional studies, 60 across the 42 observational. Of the 94 that completed or were terminated, 38 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 149 have an industry lead sponsor. The 10 most frequent:
Oregon Health and Science University is the lead sponsor of 696 studies on the registry; 131 are open to participants now.
Of its 52 completed or terminated interventional studies of FDA-regulated products, 39 (75%) have results posted.
Oregon Health and Science University has 1 study filed under Subarachnoid Hemorrhage — fewer than ten, so there is no comparison to draw.
14 of the studies in Subarachnoid Hemorrhage with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06621329Phase 3University of California, DavisTransnasal Sphenopalatine Ganglion Block for Treatment of Acute Subarachnoid Hemorrhage Associated Headache | 2027-07 |
| NCT07116408Wright State UniversityIntranasal Sphenopalatine Ganglion Blockade for Headaches Following Aneurysmal Subarachnoid Hemorrhage | 2026-11 |
| NCT06103201University of Maryland, BaltimoreHyperpolarized 13C-pyruvate Metabolic MRI With Traumatic Brain Injury | 2026-11-26 |
| NCT05230134Stanford UniversityCervical Sympathetic Block in Patients With Cerebral Vasospasm | 2026-12 |
| NCT06119061Aaron CookTelavancin Blood and Cerebrospinal Fluid Concentrations in Patients With External Ventricular Drainage | 2026-12 |
Among the 149 studies in Subarachnoid Hemorrhage with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Soluble epoxide hydrolase (sEH) is the metabolizing enzyme of epoxyeicosatrienoic acids (EETs), which may play a role in reducing neuroinflammation and regulating cerebral blood flow after subarachnoid hemorrhage (SAH). Hypotheses: Pharmacologic inhibition of the sEH enzyme is safe and will result in increased EETs availability in the blood and cerebrospinal fluid. This study is a double-blind, placebo-controlled, phase 1b randomized trial to evaluate the safety and efficacy of GSK2256294, a novel soluble epoxide hydrolase inhibitor in patients with aneurysmal SAH.
Study Description: Soluble epoxide hydrolase (sEH) is the metabolizing enzyme of epoxyeicosatrienoic acids (EETs), which may play a role in reducing neuroinflammation and regulating cerebral blood flow after subarachnoid hemorrhage (SAH).
Hypothesis: Pharmacologic inhibition of the sEH enzyme is safe and will result in increased EETs availability at the neurovascular unit, and a measured increase in the EET/DHET ratio in the serum and cerebrospinal fluid. This study is a double-blind, placebo-controlled, phase 1b randomized trial to evaluate the safety and of GSK2256294, an inhibitor of soluble epoxide hydrolase, in patients with aneurysmal SAH.
Objectives:
Primary Objective:
Determine the safety of administration of GSK2256294 in patients with aneurysmal SAH.
Secondary Objective:
Determine the pharmacodynamic effect of administration of GSK2256294 in patients with aneurysmal SAH on reducing EETs metabolism and biomarkers of cerebrovascular inflammation and endothelial injury.
Tertiary Objective:
Provide preliminary estimates of clinical endpoints to inform the design of a larger trial
Endpoints:
Primary Endpoints:
Determination of safety
Secondary endpoints:
Tertiary, exploratory endpoints:
Clinical outcomes associated with SAH including neurologic status, disposition, vital status and incidence of delayed cerebral ischemia.
20 subjects will be randomized. Patients age 18 or above with confirmed ruptured aneurysms will be approached to provide written informed consent
Phase: Phase 1B
Description of Sites/Facilities Enrolling Participants: The study will take place at Oregon Health \& Science University Hospital, with enrollment of patients admitted to the OHSU NSICU, a part of a comprehensive stroke center certified by the American Heart Association and Joint Commission for Accreditation of Healthcare Organizations, with a catchment area including the state of Oregon, Southwest Washington and Northern California. Approximately 80-100 patients with aneurysmal SAH are admitted each year.
Description of Study Intervention: Twenty patients will be equally randomized to receive once daily either 10 mg dose of GSK2256294 or placebo enterally for a duration of 10 days.
Study Duration: 24 months
Participant Duration: 90 days
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
10mg capsules of GSK2256294 will be administered in a single dose once daily enterally for a duration of 10 days.
Drug: GSK2256294
10mg matched placebo capsules will be administered in a single dose once daily enterally for a duration of 10 days.
Drug: Placebo
GSK2256294 will be administered in a single dose once daily enteral for a duration of 10 days.
Placebo will be administered in a single dose once daily enteral for a duration of 10 days.
Participants With Adverse Events
Summary tables and listings will be provided for all reported adverse events, defined as adverse events that start on or after the first administration of study drug. The reported adverse event term will be assigned a standardized preferred term. Adverse events will be summarized based on the number and percentage of patients experiencing the event. In the event a patient experiences repeat episodes of the same adverse event, then the event with the highest severity grade and strongest causal relationship to study treatment will be used for purposes of incidence tabulations. All deaths will be reported in a patient listing, which will include the primary cause of death and the number of days between the date of the last dose of study drug and death.
Time frame: 90 days
Study Day 7 and Study Day 10 Serum and CSF EET/ Dihyroxyeicosatrienoic (DHET) Ratio, by Mass Spectroscopic Analysis (ng/mL)
Day 7 and day 10 serum EET/DHET ratios will be measured by liquid chromatography and mass spectroscopy of collected blood samples. Day 7 and day 10 CSF EET/DHET ratios will be measured by liquid chromatography and mass spectroscopy of collected CSF samples.
Time frame: 10 days
Study Day 7 and Study Day 10 Serum Epoxyoctadecenoic Acid (EPOME) to Dihydroxyoctadec-12-enoic Acid (DPOME) Ratio, by Mass Spectroscopic Analysis (ng/mL)
Study day 7 and study day 10 serum epoxyoctadecenoic acid (EPOME) to dihydroxyoctadec-12-enoic acid (DPOME) ratio, will be measure by mass spectroscopic analysis of collected blood samples.
Time frame: 10 days
Serum Biomarkers of Endothelial Injury From Blood Samples Obtained on Study Day 7 and Study Day 10
The following serum biomarkers will be obtained from collected blood samples by Luminex assay: e-selectin, p-selectin, Vascular cell adhesion marker (VCAM-1), Platelet endothelial cell adhesion marker (PECAM-1, CD31), intercellular adhesion molecule (ICAM-1).
Time frame: 10 days
CSF Biomarkers of Neuroinflammation, From Blood Samples Obtained on Study Day 7 and Study Day 10
The following CSF biomarker will be obtained from collected CSF samples by Luminex assay: Tumor necrosis factor alpha (TNF-α) (pg/mL), Interleukin 1β (IL-1β) (pg/mL), Interferon gamma (IFN-γ) (pg/mL), Interleukin 6 (IL-6) (pg/mL), Interleukin 8 (IL-8) (pg/mL), Monocyte chemoattractant protein 1 (MCP-1) (pg/mL)
Time frame: 10 days
Hospital Length of Stay in Days
The hospital length of stay will be recorded in days, at the time of hospital discharge.
Time frame: 90 days
Discharge Disposition
The disposition from the hospital in one of the following categories: home, home with services, rehab, long term acute care facility, skilled nursing facility, hospice, death
Time frame: 90 days
Number of Participants With New Stroke on Hospital Discharge Imaging
The last head CT or other brain imaging to detect the presence of a new area of cerebral infarction will be reviewed at the time of hospital discharge. A cerebral infarction will be defined as a one identified on hospital discharge that was not present on imaging between 24-48 hours after aneurysm occlusion, and not attributable to other causes such as surgical clipping or endovascular treatment. Hypodensities resulting from extraventricular drains or residual intraparencyhmal hematomas will not be considered new strokes.
Time frame: 90 days
Modified Rankin Scale (mRS) at Hospital Discharge and 90 Day Follow up
The mRS score will be determined by patient or surrogate interview, at both hospital discharge and 90 day follow up. Scores will be assigned based on the following: 0 - no symptoms, 1 - no significant disability, able to carry out all usual activities despite some symptoms, 2 - slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities, 3 - moderate disability, requires some help, but able to walk unassisted, 4 - moderately severe disability, unable to attend to own bodily needs without assistance, and unable to walk unassisted, 5 - severe disability, requires constant nursing care and attention, bedridden, incontinent, 6 - deceased.
Time frame: 90 days
Extended Glasgow Outcome Scale (GOSE) Score at 90 Day Follow up
At 90 day follow up, the GOSE will be determined by patient or surrogate telephone interview, based on a structured interview of 19 questions. The GOSE is a scale of 1-8 where 1 - deceased, 2 - vegetative state, 3 - low severe disability, 4 - upper severe disability, 5 - low moderate disability, 6 -upper moderate disability, 7 - low good recovery, 8 - upper good recovery.
Time frame: 90 days
| Milestone | GSK2256294 | Placebo |
|---|---|---|
| Started | 10 | 10 |
| Completed | 10 | 8 |
| Not completed | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Death | 0 | 1 |
Summary tables and listings will be provided for all reported adverse events, defined as adverse events that start on or after the first administration of study drug. The reported adverse event term will be assigned a standardized preferred term. Adverse events will be summarized based on the number and percentage of patients experiencing the event. In the event a patient experiences repeat episodes of the same adverse event, then the event with the highest severity grade and strongest causal relationship to study treatment will be used for purposes of incidence tabulations. All deaths will be reported in a patient listing, which will include the primary cause of death and the number of days between the date of the last dose of study drug and death.
| Participants | GSK2256294 | Placebo |
|---|---|---|
| Venous Thromboembolism | 2 | 0 |
| Myocardial Infarction | 0 | 0 |
| Seizure | 1 | 1 |
| Any Documented Infection | 4 | 6 |
| Cerebral Salt Wasting | 3 | 2 |
| Leukopenia | 0 | 1 |
| Aneurysm Rebleed | 0 | 1 |
| Acute Respiratory Distress Syndrome | 0 | 1 |
| Death | 0 | 1 |
Day 7 and day 10 serum EET/DHET ratios will be measured by liquid chromatography and mass spectroscopy of collected blood samples. Day 7 and day 10 CSF EET/DHET ratios will be measured by liquid chromatography and mass spectroscopy of collected CSF samples.
| ration | GSK2256294 | Placebo |
|---|---|---|
| Study day 7 CSF 14,15-EET/DHET ratio | .17 ± .07 | .19 ± .16 |
| Study day 10 CSF 14,15-EET/DHET ratio | .45 ± .78 | .52 ± 1.04 |
| Study day 7 serum 14,15-EET/DHET ratio | .30 ± .11 | .12 ± .03 |
| Study day 10 serum 14,15-EET/DHET ratio | .27 ± .07 | .12 ± .02 |
Study day 7 and study day 10 serum epoxyoctadecenoic acid (EPOME) to dihydroxyoctadec-12-enoic acid (DPOME) ratio, will be measure by mass spectroscopic analysis of collected blood samples.
| ration | GSK2256294 | Placebo |
|---|---|---|
| Day 7 serum 12,13 EpOME/DiHOME ratio | 6.0 ± 4.3 | 1.8 ± .92 |
| Day 10 serum 12,13 EpOME/DiHOME ratio | 8.7 ± 7.1 | 1.7 ± .90 |
The following serum biomarkers will be obtained from collected blood samples by Luminex assay: e-selectin, p-selectin, Vascular cell adhesion marker (VCAM-1), Platelet endothelial cell adhesion marker (PECAM-1, CD31), intercellular adhesion molecule (ICAM-1).
| ng/mL | GSK2256294 | Placebo |
|---|---|---|
| Serum Day 7 ICAM | 8.4 ± 7.5 | 8.3 ± 6.8 |
| Serum Day 10 ICAM | 17.8 ± 27 | 6.7 ± 6.6 |
| Serum Day 7 VCAM | 8.3 ± 3.0 | 7.9 ± 2.0 |
| Serum Day 10 VCAM | 8.9 ± 2.9 | 7.9 ± 2.1 |
| Serum Day 7 PECAM-1 | 1.4 ± .56 | 1.7 ± .90 |
| Serum Day 10 PECAM-1 | 1.7 ± .90 | 1.6 ± .65 |
| Serum Day 7 E-Selectin | 46.6 ± 25.3 | 48.0 ± 33.0 |
| Serum Day 10 E-Selectin | 53.0 ± 23.8 | 44.7 ± 30.3 |
| Serum Day 7 P-Selectin | 1.4 ± .83 | 1.1 ± .28 |
| Serum Day 10 P-Selectin | 1.7 ± .90 | 2.0 ± 2.2 |
The following CSF biomarker will be obtained from collected CSF samples by Luminex assay: Tumor necrosis factor alpha (TNF-α) (pg/mL), Interleukin 1β (IL-1β) (pg/mL), Interferon gamma (IFN-γ) (pg/mL), Interleukin 6 (IL-6) (pg/mL), Interleukin 8 (IL-8) (pg/mL), Monocyte chemoattractant protein 1 (MCP-1) (pg/mL)
| pg / mL | GSK2256294 | Placebo |
|---|---|---|
| CSF Day 7 IFN-gamma | 1.9 ± 1.0 | 4.6 ± 6.8 |
| CSF Day 10 IFN-gamma | 1.5 ± .84 | 5.8 ± 12.9 |
| CSF Day 7 IL-1b | 1.6 ± .82 | 5.0 ± 9.6 |
| CSF Day 10 IL-1b | 1.0 ± .50 | 4.4 ± 9.2 |
| CSF Day 7 IL-6 | 2991.2 ± 3420.0 | 3417.9 ± 4110.2 |
| CSF Day 10 IL-6 | 2089.4 ± 3248.4 | 2051.6 ± 3570.7 |
| CSF Day 7 IL-8 | 1652.4 ± 1374.4 | 3971.0 ± 3298.9 |
| CSF Day 10 IL-8 | 1093.6 ± 775.3 | 1485.8 ± 1002.2 |
| CSF Day 7 TNF-alpha | 7.8 ± 2.6 | 13.1 ± 15.6 |
| CSF Day 10 TNF-alpha | 5.9 ± 2.8 | 8.1 ± 9.9 |
The hospital length of stay will be recorded in days, at the time of hospital discharge.
| days | GSK2256294 | Placebo |
|---|---|---|
| Hospital Length of Stay in Days | 16.9 ± 3.3 | 28.8 ± 19.8 |
The disposition from the hospital in one of the following categories: home, home with services, rehab, long term acute care facility, skilled nursing facility, hospice, death
| Participants | GSK2256294 | Placebo |
|---|---|---|
| Discharged to home | 7 | 2 |
| Discharged to rehab, long term acute care facility, skilled nursing facility, hospice, death | 3 | 7 |
The last head CT or other brain imaging to detect the presence of a new area of cerebral infarction will be reviewed at the time of hospital discharge. A cerebral infarction will be defined as a one identified on hospital discharge that was not present on imaging between 24-48 hours after aneurysm occlusion, and not attributable to other causes such as surgical clipping or endovascular treatment. Hypodensities resulting from extraventricular drains or residual intraparencyhmal hematomas will not be considered new strokes.
| Participants | GSK2256294 | Placebo |
|---|---|---|
| Number of Participants With New Stroke on Hospital Discharge Imaging | 1 | 1 |
The mRS score will be determined by patient or surrogate interview, at both hospital discharge and 90 day follow up. Scores will be assigned based on the following: 0 - no symptoms, 1 - no significant disability, able to carry out all usual activities despite some symptoms, 2 - slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities, 3 - moderate disability, requires some help, but able to walk unassisted, 4 - moderately severe disability, unable to attend to own bodily needs without assistance, and unable to walk unassisted, 5 - severe disability, requires constant nursing care and attention, bedridden, incontinent, 6 - deceased.
| units on a scale | GSK2256294 | Placebo |
|---|---|---|
| Hospital Discharge mRS | 3.4 ± 1.5 | 4.1 ± 1.4 |
| 90 day follow-up mRS | 2.2 ± 1.6 | 3.3 ± 1.7 |
At 90 day follow up, the GOSE will be determined by patient or surrogate telephone interview, based on a structured interview of 19 questions. The GOSE is a scale of 1-8 where 1 - deceased, 2 - vegetative state, 3 - low severe disability, 4 - upper severe disability, 5 - low moderate disability, 6 -upper moderate disability, 7 - low good recovery, 8 - upper good recovery.
| score on a scale | GSK2256294 | Placebo |
|---|---|---|
| Extended Glasgow Outcome Scale (GOSE) Score at 90 Day Follow up | 5.4 ± 2.4 | 4.1 ± 2.4 |
Collected over Adverse event data was collected up to 90 days after hospital discharge at the time of followup phone visit. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GSK2256294 | 0/10 (0%) | 4/10 (40%) | 0/10 (0%) |
| Placebo | 1/9 (11.1%) | 5/9 (55.6%) | 0/10 (0%) |
| Event | GSK2256294 | Placebo |
|---|---|---|
| Urinary Tract InfectionInfections and infestations | 1/10 | 2/9 |
| Delayed Cerebral IschemiaNervous system disorders | 2/10 | 1/9 |
| Deep Vein ThrombosisBlood and lymphatic system disorders | 2/10 | 0/9 |
| Rebleed of Unsecured AneurysmNervous system disorders | 0/10 | 1/9 |
| Aspiration PneumoniaInfections and infestations | 1/10 | 1/9 |
| LeukopeniaBlood and lymphatic system disorders | 0/10 | 1/9 |
| Acute Respiratory Distress SyndromeRespiratory, thoracic and mediastinal disorders | 0/10 | 1/9 |
| Pseudomonas Ventriculitis, Bacteremia, Urinary Tract InfectionInfections and infestations | 0/10 | 1/9 |
| Central Line Associated Bloodstream InfectionInfections and infestations | 1/10 | 0/9 |
1 subject in the placebo group died on study day 9 after having received 9 of 10 doses of study drug. Data is included for this subject throughout the analysis
| Age, Continuous(years) | GSK2256294 | Placebo | Total |
|---|---|---|---|
| Mean | 61.2 ± 11.2 | 60.4 ± 11.4 | 60.8 ± 11.1 |
| Sex: Female, Male(Participants) | GSK2256294 | Placebo | Total |
|---|---|---|---|
| Female | 6 | 6 | 12 |
| Male | 4 | 3 | 7 |
| Ethnicity (NIH/OMB)(Participants) | GSK2256294 | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 2 |
| Not Hispanic or Latino | 10 | 7 | 17 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | GSK2256294 | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 8 | 8 | 16 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Region of Enrollment(participants) | GSK2256294 | Placebo | Total |
|---|---|---|---|
| United States | 10 | 9 | 19 |
| Body Mass Index (BMI)(kg/m^2) | GSK2256294 | Placebo | Total |
|---|---|---|---|
| Mean | 28.8 ± 6.6 | 27.7 ± 4.7 | 28.2 ± 5.6 |
| Smoking(Participants) | GSK2256294 | Placebo | Total |
|---|---|---|---|
| Never/Passive Smoker | 2 | 5 | 7 |
| Active Smoker | 5 | 3 | 8 |
| Former Smoker | 3 | 1 | 4 |
| History of Hypertension(Participants) | GSK2256294 | Placebo | Total |
|---|---|---|---|
| Count of participants | 6 | 9 | 15 |
16 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2018 to primary completion in Apr 2019, 11 months.
Results were first posted in Jan 2021, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gsk-2256294
Oregon Health and Science University →